[강소제약사 리뷰] 동물신약 8년 장기전…약한 재무체력 과제｜유유제약④

Yuyu Pharmaceutical's long-term pivot to the Feline Medicine market highlights the strategic challenge of balancing high-cost R&D with deteriorating cash flow. As drug development is expected to take up to a decade, securing stable liquidity becomes the decisive factor in whether a mid-sized pharma company can successfully transition into the high-growth pet healthcare sector.